Positive Press Coverage Somewhat Unlikely to Affect Fulgent Genetic (FLGT) Stock Price
News headlines about Fulgent Genetic (NASDAQ:FLGT) have trended positive on Saturday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Fulgent Genetic earned a media sentiment score of 0.35 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.1678306875585 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
A number of brokerages have recently issued reports on FLGT. Piper Jaffray Companies reissued an “overweight” rating and issued a $7.00 target price (down from $10.00) on shares of Fulgent Genetic in a report on Wednesday, August 9th. ValuEngine raised Fulgent Genetic from a “sell” rating to a “hold” rating in a report on Monday, October 2nd. Zacks Investment Research raised Fulgent Genetic from a “sell” rating to a “hold” rating in a report on Tuesday, September 26th. Finally, Credit Suisse Group dropped their target price on Fulgent Genetic from $11.00 to $10.00 and set an “outperform” rating for the company in a report on Tuesday, August 8th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $10.67.
Shares of Fulgent Genetic (NASDAQ:FLGT) traded up 0.84% during trading on Friday, hitting $4.79. The stock had a trading volume of 32,019 shares. The stock’s 50-day moving average is $4.90 and its 200-day moving average is $4.90. The stock’s market capitalization is $84.97 million. Fulgent Genetic has a 12-month low of $4.37 and a 12-month high of $13.90.
Fulgent Genetic (NASDAQ:FLGT) last issued its quarterly earnings results on Monday, August 7th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.02. The business had revenue of $4.64 million during the quarter, compared to analysts’ expectations of $5.03 million. Fulgent Genetic had a negative return on equity of 0.02% and a negative net margin of 0.42%. Analysts predict that Fulgent Genetic will post $0.14 EPS for the current fiscal year.
In other Fulgent Genetic news, CFO Paul Kim sold 6,134 shares of the business’s stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $5.71, for a total transaction of $35,025.14. Following the completion of the transaction, the chief financial officer now directly owns 388,602 shares in the company, valued at $2,218,917.42. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Fulgent Genetic Company Profile
Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.
Receive News & Ratings for Fulgent Genetic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetic and related companies with Analyst Ratings Network's FREE daily email newsletter.